Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy

Table 2 TG and Non-HDLC at each visit during treatment in 5 subjects, where the Lovaza sequence was 4,4,4,4,4,4,4 g/day

Visit	Dosage (g/day)	TG (mg/dl)				Non-HDLC (mg/dl)
Visit	Dosage (g/day)	Mean ± SD	median	% change from Visit 0	p (vs Visit 0)	Mean ± SD	median	% change from Visit 0	p (vs Visit 0)
0	0	1390 ±766	1170			320 ±134	253
1	4	234 ±97	227	−83%	<.0001	177 ±65	201	−45%	.001
2	4	135 ±71	107	−90%	<.0001	152 ±10	147	−53%	.0002
3	4	158 ±51	142	−89%	<.0001	163 ±19	171	−49%	.0004
4	4	164 ±48	155		<.0001	162 ±34	169		.0004
5	4	180 ±96	144		<.0001	170 ±44	151		.0007
6	4	194 ±166	114		<.0001	156 ±36	159		.0005
7	4	179 ±120	136		<.0001	139 ±30	148		.0004
		TG decreasing slope during the first 3 months, when dose changed from 0 to 4 g/day, p=.0013				Non-HDLC decreasing slope during the first 3 months, when dose changed from 0 to 4 g/day, p=.01

ISSN: 1476-511X